ScoreWhy is Lincoln Pharmaceuticals Ltd ?
1
The company is Net-Debt Free
2
Poor long term growth as Net Sales has grown by an annual rate of 9.61% and Operating profit at 0.88% over the last 5 years
3
Flat results in Mar 26
- ROCE(HY) Lowest at 15.30%
- PBT LESS OI(Q) At Rs 20.90 cr has Fallen at -9.64%
4
With ROE of 11.6, it has a Attractive valuation with a 1.7 Price to Book Value
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 5.95%, its profits have risen by 6.7% ; the PEG ratio of the company is 2.2
5
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 1.57% over the previous quarter and collectively hold 6.28% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Lincoln Pharma. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Lincoln Pharma. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Lincoln Pharma.
5.95%
0.14
42.88%
Sensex
-7.55%
-0.58
13.06%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
9.61%
EBIT Growth (5y)
0.88%
EBIT to Interest (avg)
57.93
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.31
Sales to Capital Employed (avg)
0.97
Tax Ratio
23.98%
Dividend Payout Ratio
4.38%
Pledged Shares
0
Institutional Holding
6.28%
ROCE (avg)
21.16%
ROE (avg)
14.03%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
14
Industry P/E
34
Price to Book Value
1.68
EV to EBIT
12.44
EV to EBITDA
10.60
EV to Capital Employed
1.99
EV to Sales
1.54
PEG Ratio
2.15
Dividend Yield
0.28%
ROCE (Latest)
15.97%
ROE (Latest)
11.60%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
PAT(Latest six months)
At Rs 40.23 cr has Grown at 24.36%
DEBTORS TURNOVER RATIO(HY)
Highest at 4.16 times
NET SALES(Q)
Highest at Rs 187.28 cr
-3What is not working for the Company
ROCE(HY)
Lowest at 15.30%
PBT LESS OI(Q)
At Rs 20.90 cr has Fallen at -9.64%
Loading Valuation Snapshot...
Here's what is working for Lincoln Pharma.
Profit After Tax (PAT) - Latest six months
At Rs 40.23 cr has Grown at 24.36%
Year on Year (YoY)MOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 187.28 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Debtors Turnover Ratio- Half Yearly
Highest at 4.16 times
in the last five half yearly periodsMOJO Watch
Company has been able to settle its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Lincoln Pharma.
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 20.90 cr has Fallen at -9.64%
Year on Year (YoY)MOJO Watch
Near term PBT trend is negative
PBT less Other Income (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
